BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 38226027)

  • 1. Low-dose naltrexone for treatment of pain in patients with fibromyalgia: a randomized, double-blind, placebo-controlled, crossover study.
    Bested K; Jensen LM; Andresen T; Tarp G; Skovbjerg L; Johansen TSD; Schmedes AV; Storgaard IK; Madsen JS; Werner MU; Bendiksen A
    Pain Rep; 2023; 8(4):e1080. PubMed ID: 38226027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose naltrexone for the treatment of fibromyalgia: protocol for a double-blind, randomized, placebo-controlled trial.
    Bruun KD; Amris K; Vaegter HB; Blichfeldt-Eckhardt MR; Holsgaard-Larsen A; Christensen R; Toft P
    Trials; 2021 Nov; 22(1):804. PubMed ID: 34781989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of low-dose naltrexone and transcranial direct current stimulation in fibromyalgia: a randomized, double-blinded, parallel clinical trial.
    Paula TMH; Castro MS; Medeiros LF; Paludo RH; Couto FF; Costa TRD; Fortes JP; Salbego MO; Behnck GS; Moura TAM; Tarouco ML; Caumo W; Souza A
    Braz J Anesthesiol; 2023; 73(4):409-417. PubMed ID: 35988815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose naltrexone for induction of remission in Crohn's disease.
    Parker CE; Nguyen TM; Segal D; MacDonald JK; Chande N
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD010410. PubMed ID: 29607497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose naltrexone for induction of remission in Crohn's disease.
    Segal D; Macdonald JK; Chande N
    Cochrane Database Syst Rev; 2014 Feb; (2):CD010410. PubMed ID: 24558033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.
    Younger J; Noor N; McCue R; Mackey S
    Arthritis Rheum; 2013 Feb; 65(2):529-38. PubMed ID: 23359310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia.
    Partridge S; Quadt L; Bolton M; Eccles J; Thompson C; Colasanti A; Bremner S; Jones CI; Bruun KD; Van Marwijk H
    Heliyon; 2023 May; 9(5):e15638. PubMed ID: 37206027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study).
    Colomer-Carbonell A; Sanabria-Mazo JP; Hernández-Negrín H; Borràs X; Suso-Ribera C; García-Palacios A; Muchart J; Munuera J; D'Amico F; Maes M; Younger JW; Feliu-Soler A; Rozadilla-Sacanell A; Luciano JV
    BMJ Open; 2022 Jan; 12(1):e055351. PubMed ID: 34992118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Low-Dose Naltrexone and Predictors of Treatment Success or Discontinuation in Fibromyalgia and Other Chronic Pain Conditions: A Fourteen-Year, Enterprise-Wide Retrospective Analysis.
    Driver CN; D'Souza RS
    Biomedicines; 2023 Apr; 11(4):. PubMed ID: 37189705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pilot Study of Low-dose Naltrexone for the Treatment of Chronic Pain Due to Arthritis: A Randomized, Double-blind, Placebo-controlled, Crossover Clinical Trial.
    Beaudette-Zlatanova B; Lew RA; Otis JD; Branch-Elliman W; Bacorro E; Dubreuil M; Eyvazzadeh C; Kaur M; Lazzari AA; Libbey C; Monach PA
    Clin Ther; 2023 May; 45(5):468-477. PubMed ID: 37045708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review.
    Yang J; Shin KM; Do A; Bierle DM; Abu Dabrh AM; Yin Z; Bauer BA; Mohabbat AB
    J Pain Res; 2023; 16():1017-1023. PubMed ID: 36974308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-Dose Naltrexone in Rheumatological Diseases.
    de Carvalho JF; Skare T
    Mediterr J Rheumatol; 2023 Mar; 34(1):1-6. PubMed ID: 37223594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Low Dose Naltrexone for Chronic Pain.
    N Irwin M; A Cooke D; Berland D; D Marshall V; A Smith M
    J Pain Palliat Care Pharmacother; 2024 Mar; 38(1):13-19. PubMed ID: 38301136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effects of Low Dose Naltrexone on Opioid Induced Hyperalgesia and Fibromyalgia.
    Jackson D; Singh S; Zhang-James Y; Faraone S; Johnson B
    Front Psychiatry; 2021; 12():593842. PubMed ID: 33664680
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of low-dose naltrexone on quality of life in high-grade glioma patients: a placebo-controlled, double-blind randomized trial.
    Peters KB; Affronti ML; Woodring S; Lipp E; Healy P; Herndon JE; Miller ES; Freeman MW; Randazzo DM; Desjardins A; Friedman HS
    Support Care Cancer; 2022 Apr; 30(4):3463-3471. PubMed ID: 35001215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral naltrexone to enhance analgesia in patients receiving continuous intrathecal morphine for chronic pain: a randomized, double-blind, prospective pilot study.
    Hamann S; Sloan P
    J Opioid Manag; 2007; 3(3):137-44. PubMed ID: 18027539
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose naltrexone, an opioid-receptor antagonist, is a broad-spectrum analgesic: a retrospective cohort study.
    Martin SJ; McAnally HB; Okediji P; Rogosnitzky M
    Pain Manag; 2022 Sep; 12(6):699-709. PubMed ID: 35289682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone.
    Oaks Z; Stage A; Middleton B; Faraone S; Johnson B
    Discov Med; 2018 Nov; 26(144):197-206. PubMed ID: 30695679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Sublingual Cyclobenzaprine for the Treatment of Fibromyalgia: Results From a Randomized, Double-Blind, Placebo-Controlled Trial.
    Lederman S; Arnold LM; Vaughn B; Kelley M; Sullivan GM
    Arthritis Care Res (Hoboken); 2023 Nov; 75(11):2359-2368. PubMed ID: 37165930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia.
    Parkitny L; Younger J
    Biomedicines; 2017 Apr; 5(2):. PubMed ID: 28536359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.